scholarly journals The neuro-inflammasome in Alzheimer’s disease and cerebral stroke

2020 ◽  
Author(s):  
Jong-hoon Lee
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Side Effects ◽  
Psychiatric Symptoms ◽  
Neuropsychiatric Symptoms ◽  
Clinical Staging ◽  
Cerebral Stroke ◽  
Study Results ◽  
Before And After ◽  
Neuro Inflammation

Aim/Background: This study investigated patients with Alzheimer’s disease (AD) who were treated with 4,4’-diaminodiphenyl sulfone (DDS) as a neuro-inflammasome competitor according to the 2018 'NIA-AA Research Framework' to differentiate neuro-psychiatric symptoms from drug side effects. Methods: According to the diagnostic criteria of AD, the Seoul study analysed AD and anti-AD drugs (AADs) in the EDI database of the Sorokdo National Hospital archived from January 2005 to June 2020 and searched using the ICD-9 and 10 codes. Numeric clinical staging (NCS) was determined by managing the AD symptoms and neuropsychiatric symptoms caused by AADs with a new biomarker, (D). We report related cases of cerebral infarction and the function of DDS as a neuro-inflammasome competitor in the Seoul study. Results: DDS acts as a neuro-inflammasome competitor; this effect can be inferred by comparing the prevalence of AD in patients who have been prescribed DDS and those who have not. By the introduction of (D), the progression of AD was monitored through NCS staging; AAD side effects and neuropsychiatric symptoms were distinguished and treated with DDS. AD can occasionally be exacerbated by AADs, and mild cognitive impairment can be alleviated by DDS. We clinically confirmed the role of DDS as a neuro-inflammasome competitor before and after cerebral infarcts in the Seoul study. Conclusions: DDS acts as a blocker of canonical/non-canonical ubiquitylation; NLRP3 inflammasome formation; Higgins’ cascade; and iron-rich, strongly magnetic nanoparticles released by the splitting of red blood cells. (D) can be used to guide the prevention and treatment of AD with DDS. This study demonstrates the use of NCS and neuro-inflammation treatment as a preventive and therapeutic method for AD.

scholarly journals The neuro-inflammasome in Alzheimer’s disease and cerebral stroke

2021 ◽  
Author(s):  
Jong-hoon Lee
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Side Effects ◽  
Neuropsychiatric Symptoms ◽  
Clinical Staging ◽  
Cerebral Stroke ◽  
Diaminodiphenyl Sulfone

Aim/Background: This Review investigated a patient with Alzheimer’s disease (AD) treated with 4,4’-diaminodiphenyl sulfone (DDS) as a neuro-inflammasome competitor.Methods: We monitored AD’s progression through Numeric Clinical staging (NCS) with a new biomarker. NCS was determined by the AD symptoms and neuropsychiatric (NP) symptoms caused by anti-AD drugs (AAD) as a biomarker (D). We also monitored the function of DDS for Stroke in a no-intake emergency state.Results: By introducing (D), AD's progression was monitored through NCS staging; AAD side effects and neuropsychiatric symptoms were distinguished. DDS was stopped in the Stroke with NCS 6 by AAD, and it rapidly proceeds to cerebral infarct.Conclusions: AADs can occasionally exacerbate AD and Stroke. DDS can alleviate mild cognitive impairment (MCI), early AD and Stroke. We clinically confirmed the role of DDS as a neuro-inflammasome competitor after Stroke. DDS keep neuronal survivals within 24 - 55 hours in the Seoul cohort.

scholarly journals The neuro-inflammasome in Alzheimer’s disease and cerebral Stroke

2021 ◽  
Author(s):  
JONG HOON LEE ◽  
Chul Joong Lee ◽  
Jungwuk Park ◽  
So Jeong Lee ◽  
Su-hee Choi
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Side Effects ◽  
Neuropsychiatric Symptoms ◽  
Clinical Staging ◽  
Cerebral Stroke ◽  
Diaminodiphenyl Sulfone

Abstract Aim/Background: This Review investigated a patient with Alzheimer’s disease (AD) treated with 4,4’-diaminodiphenyl sulfone (DDS) as a neuro-inflammasome competitor.Methods: We monitored AD’s progression through Numeric Clinical staging (NCS) with a new biomarker. NCS was determined by the AD symptoms and neuropsychiatric (NP) symptoms caused by anti-AD drugs (AAD) as a biomarker (D). We also monitored the function of DDS for Stroke in a no-intake emergency state.Results: By introducing (D), AD's progression was monitored through NCS staging; AAD side effects and neuropsychiatric symptoms were distinguished. DDS was stopped in the Stroke with NCS 6 by AAD, and it rapidly proceeds to cerebral infarct.Conclusions: AADs can occasionally exacerbate AD and Stroke. DDS can alleviate mild cognitive impairment (MCI), early AD and Stroke. We clinically confirmed the role of DDS as a neuro-inflammasome competitor after Stroke. DDS keep neuronal survivals within 24 - 55 hours in the Seoul cohort.

scholarly journals The Neuroinflammasome in Alzheimer’s Disease and Cerebral Stroke

2021 ◽  
pp. 159-167
Author(s):  
Jong-hoon Lee ◽  
Chul Joong Lee ◽  
Jungwuk Park ◽  
So Jeong Lee ◽  
Su-hee Choi
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Neuropsychiatric Symptoms ◽  
Clinical Staging ◽  
Cerebral Stroke ◽  
Study Cohort ◽  
Diaminodiphenyl Sulfone

<b><i>Aim/Background:</i></b> This review investigated a patient with Alzheimer’s disease (AD) treated with 4,4’-diaminodiphenyl sulfone (DDS) as a neuroinflammasome competitor. <b><i>Methods:</i></b> We monitored AD’s progression through numeric clinical staging (NCS) with a new biomarker. NCS was determined by the presence of AD symptoms and neuropsychiatric (NP) symptoms caused by anti-AD (AAD) drugs (D) as a biomarker. We also monitored the function of DDS for stroke in a no-intake emergency state. <b><i>Results:</i></b> By introducing (D), AD’s progression was monitored through NCS staging. AAD side effects and neuropsychiatric symptoms were identified. DDS was stopped in patients with stroke with NCS 6 caused by AAD, and it rapidly proceeded to cerebral infarct. <b><i>Conclusions:</i></b> AAD can occasionally exacerbate AD and stroke. DDS can alleviate mild cognitive impairment (MCI), early AD and stroke. We clinically confirmed the role of DDS as a neuroinflammasome competitor after stroke. DDS preserved neuronal survival within 24–55 h in the Seoul Study cohort.

The Ups and Downs of BACE1: Walking a Fine Line between Neurocognitive and Other Psychiatric Symptoms of Alzheimer’s Disease

2020 ◽  
pp. 107385842094094
Author(s):  
Saak V. Ovsepian ◽  
Jiri Horacek ◽  
Valerie B. O’Leary ◽  
Cyril Hoschl
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Psychiatric Symptoms ◽  
Neuropsychiatric Symptoms ◽  
Treatment Strategies ◽  
Neurocognitive Deficit ◽  
Key Characteristics ◽  
Noncognitive Symptoms ◽  
Therapeutic Leads ◽  
Rate Limiting

Although neurocognitive deficit is the best-recognized indicator of Alzheimer’s disease (AD), psychotic and other noncognitive symptoms are the prime cause of institutionalization. BACE1 is the rate-limiting enzyme in the production of Aβ of AD, and one of the promising therapeutic targets in countering cognitive decline and amyloid pathology. Changes in BACE1 activity have also emerged to cause significant noncognitive neuropsychiatric symptoms and impairments of circadian rhythms, as evident from clinical trials and reports in transgenic models. In this study, we consider key characteristics of BACE1 with its contribution to neurocognitive deficit and other psychiatric symptoms of AD. We argue that a growing list of noncognitive mental impairments related to pharmacological modulation of BACE1 might present a major obstacle in clinical translation of emerging therapeutic leads targeting this protease. The adverse effects of BACE1 inhibition on mental health call for a revision of treatment strategies that assume indiscriminate inhibition of this key protease, and stress the need for further mechanistic and translational studies.

Neuropsychiatric Symptoms, Caregiver Burden and Distress in Behavioral-Variant Frontotemporal Dementia and Alzheimer's Disease

2015 ◽  
Vol 40 (5-6) ◽  
pp. 268-275 ◽  
Author(s):  
Thais Bento Lima-Silva ◽  
Valéria Santoro Bahia ◽  
Viviane Amaral Carvalho ◽  
Henrique Cerqueira Guimarães ◽  
Paulo Caramelli ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Frontotemporal Dementia ◽  
Sex Education ◽  
Caregiver Burden ◽  
Psychiatric Symptoms ◽  
Neuropsychiatric Symptoms ◽  
Clinical Dementia Rating ◽  
Behavioral Variant Frontotemporal Dementia ◽  
Significant Difference

Background/Aims: We aimed to compare caregiver burden and distress in behavioral-variant frontotemporal dementia (bvFTD) and Alzheimer's disease (AD) and to investigate which factors contribute to caregivers' burden and distress. Methods: Fifty patients and their caregivers were invited to participate. Among the patients, 20 had a diagnosis of bvFTD and 30 had AD. Caregivers and patients were statistically equivalent for age, sex, education and dementia severity according to Clinical Dementia Rating. The protocol included the Short Zarit Burden Inventory, the Neuropsychiatric Inventory (NPI), Disability Assessment for Dementia (DAD), the Cornell Scale for Depression in Dementia (CSDD), Addenbrooke's Cognitive Examination-Revised, the Executive Interview with 25 Items, Direct Assessment of Functional Status and the Geriatric Anxiety Inventory (GAI). Results: In the NPI, caregivers of bvFTD patients reported a higher presence and severity of neuropsychiatric symptoms and caregiver distress compared to caregivers of AD patients. There was no significant difference in the perceived burden. In bvFTD, DAD and GAI scores were significantly correlated with burden, whereas in AD, burden was correlated with CSDD and NPI scores. Psychiatric symptoms were associated with distress in both groups. Conclusions: Caregivers of bvFTD patients experienced higher levels of distress than caregivers of AD patients. Patients' functional limitations were associated with burden of caregivers of bvFTD patients, whereas neuropsychiatric symptoms were associated with caregiver strain in both groups.

scholarly journals Neuropsychological Rehabilitation in Mild and Moderate Alzheimer’s Disease Patients

2007 ◽  
Vol 18 (4) ◽  
pp. 225-233 ◽  
Author(s):  
Renata Ávila ◽  
Isabel A. M. Carvalho ◽  
Cássio M.C. Bottino ◽  
Eliane C. Miotto
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Training ◽  
Neuropsychological Tests ◽  
Daily Living ◽  
Psychiatric Symptoms ◽  
Neuropsychological Rehabilitation ◽  
Elderly Outpatients ◽  
Before And After ◽  
At Home

Objective:The purpose of this study was to analyze the effect of a neuropsychological rehabilitation (NR) program on patients with Alzheimer’s disease (AD).Methods:The sample was composed of 16 elderly outpatients who participated in an open trial with rivastigmine (6 to 12 mg/day) for 4 months and were randomized to 3 different groups: 1. group NR (N= 5), 2. individualized NR (N= 6) and 3. NR at home under supervision of a relative or caregiver (N= 5). All 3 groups fulfilled the same NR protocol consisting of a once a week session. Just before and after the 22 week period of rehabilitation, all patients were evaluated using psychiatric and functional scales, and neuropsychological tests by interviewers that did not participate in the cognitive training.Results:The intervention did not produce any statistically significant change, but small gains were observed on some cognition tests, activities of daily living (ADL), and psychiatric symptoms in groups 1 and 2.Conclusion:Group NR is recommended for reducing psychiatric symptoms, and individualized NR for improving ADL. NR at home either has no associated benefits, or the training sessions were not appropriately conducted by the caregiver. However, additional research with larger samples is necessary to confirm these observations.

scholarly journals Study of Prevalence of Neuropsychiatric Symptoms in Elderly Dementia Patients

2021 ◽  
Author(s):  
Mohan Mahale ◽  
Pradeep Behal ◽  
Nitul M Bewal ◽  
Vivek Aggarwal ◽  
Anuj Singhal ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Psychiatric Symptoms ◽  
Neuropsychiatric Symptoms ◽  
Tertiary Care ◽  
Primary Caregiver ◽  
Ageing Population ◽  
Night Time ◽  
Neuropsychiatric Manifestations ◽  
B12 Deficiency

Introduction: Prevalence of dementia is increasing with rapidly ageing population. Neuropsychiatric Symptoms (NPS) are common in certain types of dementia and increases with duration of dementia in Alzheimer’s disease and are causes significant psychosocial and management issues. Aim: To study the prevalence and type of NPS in patients of dementia presenting to a Tertiary Care Hospital and to find out the association between NPS and the type of dementia and to assess the association of the caregiver stress in this setting. Materials and Methods: The present cross-sectional observational study was conducted at Tertiary Care Government Hospital of Western Maharashtra. All patients with suspected dementia were initially screened by a Mini-Cog questionnaire and patients with a score of three or less were assessed with Hindi Mental Status Examination (HMSE). The inclusion criteria were patients with HMSE of less than or equal to 23. All the diagnosed patients with dementia were screened for common psychiatric symptoms using Neuropsychiatric Inventory (NPI). The presence of NPS was noted based on either presenting complaint of the patient or as per the history given by the primary caregiver for these symptoms in last one month. These questions were administered in focused group discussion form to the primary caregiver by the physician. The data was collected and analysed using descriptive statistics and Chi-square test with SSPS 20. Results: The most common neuropsychiatric manifestation was sleep and night-time behavioural disorder (51.5%). It was followed by depression (44%). Neuropsychiatric manifestations were much more common in demented patients of probable Dementia with Lewy Bodies (DLB) and dementia with B12 deficiency. More than 50% of the patients had two or more psychiatric symptoms. The most common psychiatric symptom in patients with probable Alzheimer’s disease was sleep and night-time disturbance in 54.9%. Common neuropsychiatric manifestations seen in DLB were visual hallucinations (100%), followed by irritability (88%). More than 90% of the caregivers were not aware of the psychiatric manifestations of dementia and did not know how to cope up with these symptoms. Conclusion: NPS were more common in patients with DLB dementia and dementia with B12 deficiency, with depression been more common symptom in patients with Parkinson’s related dementia. It is therefore, very important to look for NPS in all elderly patients which can help us to diagnose dementia earlier.

scholarly journals Behavioral and Psychological Symptoms in Alzheimer’s Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Xiao-Ling Li ◽  
Nan Hu ◽  
Meng-Shan Tan ◽  
Jin-Tai Yu ◽  
Lan Tan
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Psychiatric Symptoms ◽  
Psychological Symptoms ◽  
Neuropsychiatric Symptoms ◽  
Treatment Success ◽  
Future Research ◽  
Brain Changes ◽  
Specific Symptoms

Neuropsychiatric symptoms (NPS) such as depression, apathy, aggression, and psychosis are now recognized as core features of Alzheimer’s disease (AD), and there is a general consensus that greater symptom severity is predictive of faster cognitive decline, loss of independence, and even shorter survival. Whether these symptoms result from the same pathogenic processes responsible for cognitive decline or have unique etiologies independent of AD-associated neurodegeneration is unclear. Many structural and metabolic features of the AD brain are associated with individual neuropsychiatric symptoms or symptom clusters. In addition, many genes have been identified and confirmed that are associated with symptom risk in a few cases. However, there are no single genes strongly predictive of individual neuropsychiatric syndromes, while functional and structural brain changes unique to specific symptoms may reflect variability in progression of the same pathological processes. Unfortunately, treatment success for these psychiatric symptoms may be lower when comorbid with AD, underscoring the importance of future research on their pathobiology and treatment. This review summarizes some of the most salient aspects of NPS pathogenesis.

Therapeutic Properties of Several Chemical Compounds from Salvia officinalis L. in Alzheimer’s Disease

2020 ◽  
Vol 21 ◽  
Author(s):  
Georgiana Uță ◽  
Denisa Ștefania Manolescu ◽  
Speranța Avram
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Side Effects ◽  
Chemical Compounds ◽  
Natural Compounds ◽  
Salvia Officinalis ◽  
Chemical Structures ◽  
In Silico Studies ◽  
Wide Range ◽  
Salvia Officinalis L

Background.: Currently, the pharmacological management in Alzheimer's disease is based on several chemical structures, represented by acetylcholinesterase and N-methyl-D-aspartate (NMDA) receptor ligands, with still unclear molecular mechanisms, but severe side effects. For this reason, a challenge for Alzheimer's disease treatment remains to identify new drugs with reduced side effects. Recently, the natural compounds, in particular certain chemical compounds identified in the essential oil of peppermint, sage, grapes, sea buckthorn, have increased interest as possible therapeutics. Objectives.: In this paper, we have summarized data from the recent literature, on several chemical compounds extracted from Salvia officinalis L., with therapeutic potential in Alzheimer's disease. Methods.: In addition to the wide range of experimental methods performed in vivo and in vitro, also we presented some in silico studies of medicinal compounds. Results. Through this mini-review, we present the latest information regarding the therapeutic characteristics of natural compounds isolated from Salvia officinalis L. in Alzheimer's disease. Conclusion.: Thus, based on the information presented, we can say that phytotherapy is a reliable therapeutic method in a neurodegenerative disease.

Sign in / Sign up

Export Citation Format

Share Document